This survey depicts the initiatives managed care organizations (MCOs) are planning to undertake when the first biosimilar is marketed in the United States, as of 2015. The survey shows that 93 percent of MCOs plan to undergo a review by the pharmacy and therapeutics committee.
Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015
Initiative
Percentage of resondents
Undergo review by the Pharmacy & Therapeutics committee
93%
Manage the use of the originator product via prior authorization (PA)
48%
Manage the use of the biosimilar via PA
44%
Add the product to formulary as preferred status
42%
Institute a step-edit, establishing the biosimilar as first-line compared to the originator project
38%
Add the product to appropriate standards of care (eg, guidelines, pathways)
32%
Develop physician education materials about biosimilars
28%
Develop member education materials about biosimilars
24%
Set physician reimbursement lower than the originator product
13%
Add the product to formulary as exclusive status, for aggressive contracting
11%
Set physician reimbursement at parity with the originator product
8%
Set physician reimbursement higher than the originator product
The survey in total includes data from following groups: managed care organizations (MCOs), specialty pharmacies (SPs), oncologists, oncology practice managers (OPMs), employers that sponsor health benefits.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Genentech. (May 6, 2016). Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015 [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/544305/biosimilar-marketing-initiatives-by-us-managed-care-organizations/
Genentech. "Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015." Chart. May 6, 2016. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/544305/biosimilar-marketing-initiatives-by-us-managed-care-organizations/
Genentech. (2016). Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/544305/biosimilar-marketing-initiatives-by-us-managed-care-organizations/
Genentech. "Planned Initiatives of Managed Care Organizations (Mcos) after First Biosimilar Is Marketed in The United States as of 2015." Statista, Statista Inc., 6 May 2016, https://www-statista-com.ezproxy.canberra.edu.au/statistics/544305/biosimilar-marketing-initiatives-by-us-managed-care-organizations/
Genentech, Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015 Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/544305/biosimilar-marketing-initiatives-by-us-managed-care-organizations/ (last visited November 10, 2024)
Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015 [Graph], Genentech, May 6, 2016. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/544305/biosimilar-marketing-initiatives-by-us-managed-care-organizations/
